ARTICLE | Financial News
Urogen rises in first trading day
May 4, 2017 10:24 PM UTC
Urogen Pharma Ltd. (NASDAQ:URGN) gained $0.98 to $13.98 in its first day of trading Thursday after raising $58.2 million in an upsized IPO. The oncology company priced the offering after market hours Wednesday (see BioCentury Extra, May 3).
UroGen's lead candidate MitoGel is in Phase III testing to treat upper tract urothelial carcinoma (UTUC). MitoGel has Orphan Drug designation for the indication...
BCIQ Company Profiles